» Articles » PMID: 25436773

Silica Nanoparticles As the Adjuvant for the Immunisation of Mice Using Hepatitis B Core Virus-like Particles

Overview
Journal PLoS One
Date 2014 Dec 2
PMID 25436773
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Advances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commercially available Silica nanoparticles (initial particles size of 10-20 nm) with that of aluminium hydroxide, or Alum, as well as that of complete and incomplete Freund's adjuvants for the immunisation of BALB/c mice with virus-like particles (VLPs) formed by recombinant full-length Hepatitis B virus core (HBc) protein. The induction of B-cell and T-cell responses was studied after immunisation. Silica nanoparticles were able to adsorb maximally 40% of the added HBc, whereas the adsorption capacity of Alum exceeded 90% at the same VLPs/adjuvant ratio. Both Silica and Alum formed large complexes with HBc VLPs that sedimented rapidly after formulation, as detected by dynamic light scattering, spectrophotometry, and electron microscopy. Both Silica and Alum augmented the humoral response against HBc VLPs to the high anti-HBc level in the case of intraperitoneal immunisation, whereas in subcutaneous immunisation, the Silica-adjuvanted anti-HBc level even exceeded the level adjuvanted by Alum. The adjuvanting of HBc VLPs by Silica resulted in the same typical IgG2a/IgG1 ratios as in the case of the adjuvanting by Alum. The combination of Silica with monophosphoryl lipid A (MPL) led to the same enhancement of the HBc-specific T-cell induction as in the case of the Alum and MPL combination. These findings demonstrate that Silica is not a weaker putative adjuvant than Alum for induction of B-cell and T-cell responses against recombinant HBc VLPs. This finding may have an essential impact on the development of the set of Silica-adjuvanted vaccines based on a long list of HBc-derived virus-like particles as the biological component.

Citing Articles

Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.

Wang J, Zhao Z, Wang Q, Shi J, Wong D, Cheung J Vaccines (Basel). 2025; 12(12.

PMID: 39771997 PMC: 11680411. DOI: 10.3390/vaccines12121335.


Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.

Sazegari S, Akbarzadeh Niaki M, Afsharifar A, Niazi A, Derakhshandeh A, Moradi Vahdat M Microb Cell Fact. 2023; 22(1):39.

PMID: 36841778 PMC: 9958315. DOI: 10.1186/s12934-023-02043-z.


Strategies for safe management of hospital wastewater during the COVID-19 pandemic.

Balakrishnan A, Jacob M, Kumar P, Kapoor A, Ponnuchamy M, Sivaraman P Int J Environ Sci Technol (Tehran). 2023; :1-16.

PMID: 36817164 PMC: 9925218. DOI: 10.1007/s13762-023-04803-1.


Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses.

Tng D, Low J Antiviral Res. 2022; 210:105488.

PMID: 36566118 PMC: 9776486. DOI: 10.1016/j.antiviral.2022.105488.


The Interactions between Nanoparticles and the Innate Immune System from a Nanotechnologist Perspective.

Ernst L, Casals E, Italiani P, Boraschi D, Puntes V Nanomaterials (Basel). 2021; 11(11).

PMID: 34835755 PMC: 8621168. DOI: 10.3390/nano11112991.


References
1.
Milich D, McLachlan A . The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science. 1986; 234(4782):1398-401. DOI: 10.1126/science.3491425. View

2.
Giannini S, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F . Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006; 24(33-34):5937-49. DOI: 10.1016/j.vaccine.2006.06.005. View

3.
Roseman A, Borschukova O, Berriman J, Wynne S, Pumpens P, Crowther R . Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J Mol Biol. 2012; 423(1):63-78. PMC: 3465560. DOI: 10.1016/j.jmb.2012.06.032. View

4.
Collier L, Polakoff S, Mortimer J . Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet. 1979; 1(8131):1364-8. DOI: 10.1016/s0140-6736(79)92006-3. View

5.
Wingfield P, Stahl S, Williams R, Steven A . Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly. Biochemistry. 1995; 34(15):4919-32. DOI: 10.1021/bi00015a003. View